National Association of Testing Authorities, Australia
Scope of Accreditation
Laverty Pathology
Site
North Ryde Laboratory – Healius Pathology Pty Ltd
Accreditation No.
2203
Site No.
2196
Date of Accreditation
14 Apr 1987
Contact
Ms Joanne Clarke
P: +61 (02) 90057440
Availability
Services available to external clients
Supervision
GX (General)
Scope of Accreditation
Anatomical Pathology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
07 Jan 2025
Last Activity Date
30 Sep 2021
| Service | Product | Determinant |
|---|---|---|
| Anatomical pathology - Cytopathology - Cervical cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Cervical smear; Cervical tissue; Liquid based cytology specimens from cervix | Cytological examination; Review and reporting of cervical cytological material |
| Anatomical pathology - Cytopathology - Gynaecological (non-cervical) cytological investigation for abnormalities, precancerous or cancerous changes or conditions | Liquid based cytology specimens from cervix; Vaginal smears | Cytological examination; Review and reporting of gynaecological (non-cervical tissue) cytological samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations of body fluids, exudates, washings and brushings from non-squamous mucosal sites for the detection of malignancy | Aspirates; Bronchial lavage; Cerebrospinal fluid (CSF); Ocular specimens; Other body fluids; Sputum; Urine; Vitreous specimens; Washings or brushings from other sites | Cytological examination; Review and reporting of cytology samples |
| Anatomical pathology - Cytopathology - Non-gynaecological cytological investigations on samples obtained via fine needle aspiration biopsy | Fine needle aspirates (FNA) | Cytological examination; Review and reporting of fine needle aspiration samples |
| Anatomical pathology - Cytopathology - Testing for the National Cervical Screening Program | Liquid based cytology specimens from cervix | Human papilloma virus (HPV); Cytological examination; Review and reporting of cervical cytological material |
| Self-collected vaginal swabs552C 80 | Human papilloma virus (HPV) | |
| Self-collected vaginal swabsswab 5552C | Human papilloma virus (HPV) | |
| Anatomical pathology - Tissue pathology - Examination of biopsy material | Formalin fixed tissue; Fresh tissue | Review and reporting of biopsy material to identify or exclude morphological abnormalities |
| Anatomical pathology - Tissue pathology - Gene probes using paraffin in-situ hybridisation techniques (chromogenic/silver) | Formalin-fixed paraffin-embedded (FFPE) tissues | Detection of nucleic acid targets - Various |
| Anatomical pathology - Tissue pathology - Immediate frozen section diagnosis | Fresh tissue | Intra-operative consultation and examination of biopsy material |
| Anatomical pathology - Tissue pathology - Immunohistochemical (immunofluorescence) investigation | Fresh tissue; Frozen tissue | Detection of antigenic targets - Various |
| Anatomical pathology - Tissue pathology - Immunohistochemical investigation | Formalin-fixed paraffin-embedded (FFPE) tissues; Fresh tissue; Frozen sections of fresh tissue | Detection of antigenic targets - Various |
| Infertility and pregnancy tests including assisted reproductive technology - Semen analysis (other than post vasectomy) | Semen | Agglutination; Aggregation; Colour; Differential number; Fructose; Morphology; Motility; Sperm number; Viscosity; Vitality; Volume; pH |
Chemical Pathology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
07 Jan 2025
Last Activity Date
30 Sep 2021
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Detection and/or quantitation of drugs for therapeutic monitoring | Blood | Cyclosporin |
| Tacrolimus | ||
| Serum | Phenobarbitone | |
| Digoxin | ||
| Carbamazepine; Gentamicin (cidomycin, septopal, genticyn, garamycin); Lithium; Phenobarbitone; Phenytoin (dilantin); Valproate (valproic acid, epilim); Vancomycin | ||
| Chemical pathology - Detection and/or quantitation of tumour markers | Serum | Human chorionic gonadotropin (hCG) |
| Thyroglobulin | ||
| CA125 antigen (CA125); Human epididymal protein 4; α-Fetoprotein (AFP) | ||
| CA125 antigen (CA125); CA15-3 antigen (CA15-3); CA19-9 antigen (CA19-9); Carcinoembryonic antigen (CEA); Prostate specific antigen (PSA) fractions and derived index; α-Fetoprotein (AFP) | ||
| Prostate specific antigen (PSA) fractions and derived index | ||
| β2-Microglobulin (B2M) | ||
| Human epididymal protein 4 | ||
| Urine | β2-Microglobulin (B2M) | |
| Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Plasma | Adrenocorticotropic hormone (ACTH) |
| Insulin | ||
| Parathyroid hormone (PTH) | ||
| Serum | Anti-Mullerian hormone (AMH) | |
| Cortisol | ||
| C-peptide; Cortisol; Dehydroepiandrosterone sulfate (DHEAS); Follicle stimulating hormone (FSH); Insulin; Luteinising hormone (LH); Macroprolactin; Oestradiol; Progesterone; Prolactin; Sex hormone binding globulin (SHBG); Testosterone - Total | ||
| Insulin-like growth factor 1 (IGF-1, somatomedin C) | ||
| Androstenedione; Gastrin; Growth hormone | ||
| Procalcitonin | ||
| Cortisol | ||
| Urine | Cortisol | |
| Chemical pathology - Diagnosis and management of diabetes mellitus | Serum | Fructosamine |
| Chemical pathology - Further investigation of cardiac function | Serum | Troponin |
| Creatine kinase (CK) isoenzymes | ||
| Creatine kinase MB (CKMB) | ||
| Chemical pathology - Further investigation of lipid profiles for diagnosis of types III and IV hyperlipidaemia | Serum | Lipoprotein subclasses |
| Chemical pathology - Further investigation of renal and/or hepatic function | Serum | Bile acids |
| Haptoglobins; α1-Antitrypsin | ||
| Caeruloplasmin; Haptoglobins | ||
| Alkaline phosphatase (ALP) isoenzymes | ||
| Chemical pathology - Investigation and determination of hepatic, cardiac, bone, skeletal muscle and other profiles and metabolic studies | Cerebrospinal fluid (CSF) | Glucose; Protein - Total |
| Serum | Alanine aminotransferase; Albumin; Alkaline phosphatase; Amylase; Aspartate aminotransferase; Bicarbonate; Bilirubin - Any fractions; Bilirubin - Total; Calcium - Total; Chloride; Cholesterol - Total; Creatine kinase; Creatinine; Glucose; Glutamate dehydrogenase; High sensitivity C-reactive protein (CRP); Lactate; Lactate dehydrogenase (LDH); Lipase; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urate; Urea; γ-Glutamyltransferase | |
| Osmolality | ||
| Alanine aminotransferase; Albumin; Alkaline phosphatase; Amylase; Angiotensin converting enzyme (ACE); Aspartate aminotransferase; Bicarbonate; Bilirubin - Any fractions; Bilirubin - Total; C-reactive protein (CRP); Calcium - Corrected for albumin; Calcium - Total; Chloride; Cholesterol - Total; Creatine kinase; Creatinine; Glucose; Lactate dehydrogenase (LDH); Lipase; Magnesium; Phosphate; Potassium; Protein - Total; Sodium; Triglycerides; Urate; Urea; γ-Glutamyltransferase | ||
| Calcium - Ionised; pH | ||
| Urine | Magnesium | |
| Osmolality | ||
| Calcium - Total; Chloride; Creatinine; Microalbumin; Phosphate; Potassium; Protein - Total; Sodium; Urate; Urea | ||
| Chemical pathology - Investigation for folate deficiency | Serum | Folate |
| Chemical pathology - Investigation of maternal markers to detect foetal abnormality | Serum | Free β-human chorionic gonadotropin (free β-hCG); Pregnancy associated plasma protein A (PAPP-A) |
| Chemical pathology - Iron studies | Serum | Ferritin |
| Iron; Transferrin | ||
| Iron; Transferrin | ||
| Ferritin | ||
| Chemical pathology - Markers of bone metabolism | Serum | Procollagen type 1 N-terminal propeptide (P1NP); c-Telopeptide (CTx) |
| Urine | Deoxypyridinoline (DPD) | |
| Chemical pathology - Quantitation of precursor and intermediary metabolites | Plasma | Homocysteine |
| Chemical pathology - Quantitation of vitamin B markers | Serum | Holotranscobalamin (active vitamin B12) |
| Chemical pathology - Quantitation of vitamins | Serum | Cobalamin (vitamin B12) |
| Vitamin D | ||
| Chemical pathology - Tests for thyroid function | Serum | Thyroid stimulating hormone (TSH); Thyroxine (T4) - Free; Triiodothyronine (T3) - Free |
| Thyroid stimulating hormone (TSH); Thyroxine (T4) - Free; Triiodothyronine (T3) - Free | ||
| Thyroid stimulation immunoglobulins | ||
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Serum | Rheumatoid factor |
| Anti-thyroglobulin antibodies (Tg); Anti-thyroid peroxidase antibodies (TPO) | ||
| Immunopathology - Quantitation of complement proteins | Serum | Complement components C3 and C4 |
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Faeces | Calprotectin; Elastase |
| Immunopathology - Quantitative investigations of immunoglobulins and immunoglobulins subclasses | Serum | Total immunoglobulin A; Total immunoglobulin G; Total immunoglobulin M |
| Total immunoglobulin E | ||
| Infertility and pregnancy tests including assisted reproductive technology - Diagnosis of pregnancy | Serum | Human chorionic gonadotropin (hCG) |
| Human chorionic gonadotropin (hCG) | ||
| Urine | Human chorionic gonadotropin (hCG) | |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Serum | Helicobacter pylori |
| Anti-streptolysin O (ASOT) |
Haematology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
07 Jan 2025
Last Activity Date
30 Sep 2021
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Diagnosis and management of diabetes mellitus | Blood | Glycated haemoglobin (HbA1c) |
| Glycated haemoglobin (HbA1c) | ||
| Haematology - Assessment of haemolysis or metabolic enzymes (red cell enzyme assays) | Blood | Glucose-6-phosphate dehydrogenase (G6PD) |
| Haematology - Bone marrow examination | Bone marrow; Trephine | Examination of aspirated material; Histological examination |
| Haematology - Diagnosis of thalassemia | Blood | Examination of haemoglobin H (HbH); Haemoglobin A (HbA) - Quantitation; Haemoglobin A2 (HbA2) - Quantitation; Haemoglobin F (HbF) - Quantitation; Haemoglobin H (HbH) inclusions |
| Examination of haemoglobin H (HbH); Haemoglobin A (HbA) - Quantitation; Haemoglobin A2 (HbA2) - Quantitation; Haemoglobin F (HbF) - Quantitation; Haemoglobin H (HbH) inclusions | ||
| Haematology - Examination of blood films by special staining | Blood | Malaria |
| Haematology - Foetal haemoglobin in maternal circulation | Blood | Feto-maternal haemorrhage (FMH) estimation |
| Haematology - Full blood examination | Blood | Differential number; Erythrocyte count (red blood cell count, RBCC); Haematocrit (packed cell volume, PCV); Haemoglobin (Hb); Leucocyte count (white blood cell count, WBCC); Nucleated red blood cells (NRBC); Platelet count; Red blood cell index or indices; Reticulocytes |
| Differential number; Morphology | ||
| Haematology - Haemostasis related analysis (including special coagulation testing and platelet function tests) | Blood | Platelet function (PFA) |
| Plasma | Activated protein C (APC) resistance; Anti-Xa - Apixaban; Anti-Xa - Rivaroxaban; Anti-Xa activity - Low molecular weight heparin; Anti-Xa activity - Unfractionated heparin; Anti-thrombin III; Factor II; Factor IX; Factor V; Factor VII; Factor VIII; Factor X; Factor XI; Factor XII; Lupus anticoagulant; Protein C; Protein S; Von Willebrand factor (vWF) activity - Ristocetin co-factor assay; Von Willebrand factor (vWF) antigen - Quantitation | |
| Activated partial thromboplastin time (APTT); D-dimer; Fibrinogen; International normalised ratio (INR); Prothrombin time (PT); Thrombin time (TT) | ||
| Haematology - Investigation of haemoglobinopathy (excluding thalassemia) | Blood | Haemoglobin fraction (S, C, D, E) - Quantitation; Other abnormal haemoglobins |
| Haemoglobin S (HbS) - Presence | ||
| Haematology - Investigation of haemolysis | Blood | Cold agglutinins |
| Haematology - Limited blood examination | Blood | Erythrocyte (RBC) sedimentation rate (ESR) |
| Immunohaematology - Blood group antibody detection | Blood | Duffy system; Kell system; M and N factors; Other blood group systems; Rh phenotypes |
| Immunohaematology - Blood grouping | Blood | ABO; RhD |
| Immunohaematology - Determination of compatibility of blood donor units | Blood | Direct antiglobulin test (DAT, direct Coombs test); Examination for blood group antibodies; Group checks of patient and donor; Identification of detected antibodies |
| Immunohaematology - Identification and quantitation of blood group antibodies | Blood; Plasma | Antibody elution; Antibody titration |
| Immunohaematology - Investigation of blood transfusion reactions | Blood products | Antibodies; Contamination - Microbiological |
| Immunohaematology - Issue and release of blood and blood product for transfusion | Blood products | Issue and release of blood and blood products for transfusion |
| Immunohaematology - Storage and distribution of blood and blood components | Blood products | Issue and release of blood and blood products for transfusion |
| Immunopathology - Characterisation of leucocyte surface antigens (including immunophenotyping) | Blood | Memory B cell subsets |
| T-cell receptor β (TCRb) | ||
| Blood; Bone marrow | Paroxysmal nocturnal haemoglobinuria (PNH) surface markers | |
| Assessment of lymphoid cell populations; Assessment of myeloid cell populations; CD10; CD103; CD117; CD11c; CD123; CD127; CD13; CD138; CD14; CD15; CD16; CD19; CD1a; CD2; CD20; CD200; CD22; CD23; CD235a; CD25; CD3; CD30; CD33; CD34; CD38; CD4; CD41; CD43; CD45; CD5; CD56; CD57; CD64; CD7; CD79a; CD79b; CD8; CD81; CD9; FMC7; HLA-DR antigen; Kappa light chains; Lambda light chains; MPO; Natural killer (NK) cells | ||
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Serum | Cryofibrinogen; Cryoglobulins |
| Immunopathology - Single HLA antigen typing | Blood | HLA-B27 |
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Serum | Malaria |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood | Infectious mononucleosis |
Immunology/Serology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
07 Jan 2025
Last Activity Date
30 Sep 2021
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Investigation of Helicobacter pylori colonisation or eradication | Breath | C14 |
| Immunopathology - Detection and/or quantitation and/or characterisation of autoantibodies | Serum | Anti-cyclic citrullinated peptide antibodies (CCP) |
| Anti-cardiolipin antibodies (ACA); Anti-extractable nuclear antigen antibodies (ENA); Anti-gliadin antibodies (AGA); Anti-glomerular basement membrane antibodies (anti-GBM); Anti-myeloperoxidase antibodies (MPO); Anti-proteinase 3 antibodies (PR3); Anti-tissue transglutaminase antibodies (tTG); Anti-β2-glycoprotein-I antibodies | ||
| Anti-double stranded DNA antibodies (dsDNA) | ||
| Anti-endomysial antibodies (EMA); Anti-gastric parietal cell antibodies (GPC/PCA); Anti-liver-kidney microsomes antibodies (LKM); Anti-mitochondrial antibodies (AMA, AMA M1 and/or AMA M2); Anti-neutrophil cytoplasmic antibodies (ANCA); Anti-nuclear antibodies (ANA); Anti-smooth muscle antibodies (SMA) | ||
| Anti-intrinsic factor antibodies (IF) | ||
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential drug allergens) | Serum | Amoxicilloyl group; Ampicilloyl group; Cefaclor; Chlorhexidine; Morphine; Penicilloyl G; Penicilloyl V |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential epidermal and animal protein allergens) | Serum | Budgerigar feathers; Canary bird feathers; Cat dander; Chicken feathers; Cow dander; Dog dander; Duck feathers; Finch feathers; Goose feathers; Guinea pig epithelium; Horse dander; Mouse epithelium; Parakeet feathers; Parrot feathers; Rabbit epithelium; Rat epithelium; Turkey feathers |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [egg and fowl] allergens) | Serum | Chicken; Egg; Egg white; Egg yolk |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [fish, shellfish and molluscs] allergens) | Serum | Blue mussel; Codfish; Crab; Lobster; Oyster; Salmon; Sardine (pilchard); Scallop; Shrimp; Squid; Tuna |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [meat] allergens) | Serum | Beef; Mutton; Pork |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [milk] allergens) | Serum | Casein; Cheese - Cheddar type; Cow milk |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [miscellaneous] allergens) | Serum | Cacao; Coffee; Honey; Hop (fruit cone); Mushroom; Yeasts |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [seeds, legumes and nuts] allergens) | Serum | Almond; Barley; Brazil nut; Cashew nut; Chick pea; Coconut; Gluten; Green bean; Hazelnut; Lentil; Linseed; Lupin seed; Macadamia nut; Maize; Oat; Pea; Peanut; Pecan nut; Pinenut; Pistachio; Rice; Rye; Sesame seed; Soy bean; Walnut; Wheat |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential food [spices] allergens) | Serum | Basil; Black pepper; Chilli pepper; Coriander (cilantro); Ginger; Mustard; Oregano; Paprika (sweet pepper) |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential grass pollen allergens) | Serum | Bahia grass; Bermuda grass; Cultivated oat; Johnson grass; Meadow grass; Rye grass; Timothy grass |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential insect allergens) | Serum | German cockroach; Mosquito |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential microorganism allergens) | Serum | Alternaria alternata; Anisakis; Aspergillus fumigatus; Aspergillus niger; Candida albicans; Cladosporium herbarum; Malassezia spp.; Penicillium chrysogenum (formerly Penicillium notatum); Pityrosporum orbiculare (Malassezia furfur); Staphylococcus enterotoxins; Stemphylium herbarum; Trichophyton mentagrophytes; Trichophyton rubrum; Mould mix |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential mite allergens) | Serum | Blomia tropicalis house dust mite; Dermatophagoides farinae house dust mite; Dermatophagoides pteronyssinus house dust mite |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential occupational allergens) | Serum | Chloramine-T; Formaldehyde/formalin; Hexamethylene diisocyanate (1,6-hexamethylene diisocyanate; 1,6-HDI); Latex; Methylene diphenyl diisocyanate (MDI, isocyanate MDI, diphenylmethane diisocyanate); Oxirane (ethyleneoxide); Phthalic anhydride; Sunflower seed; Toluene-2,4-diisocyanate (2,4-TDI) |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential tree pollen allergens) | Serum | Acacia; Australian pine; Eucalyptus; Maple leaf sycamore; Melaleuca; Olive; Privet; Silver birch; White pine; Willow salix |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential venom allergens) | Serum | Common wasp (yellow jacket) venom; Honey bee venom; Paper wasp venom |
| Immunopathology - Detection of immunoglobulin E specific antibodies (to potential weed pollen allergens) | Serum | Common ragweed; Goosefoot; Mugwort; Plantain - English; Saltwort (prickly); Wall pellitory |
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Serum | Detection of Bence Jones proteins |
| Detection and quantitation of free kappa and free lambda light chains; Immunoglobulin G (IgG) - Kappa; Immunoglobulin G (IgG) - Lambda | ||
| Urine | Detection of Bence Jones proteins | |
| Microbiology - Mycology - Detection, isolation and/or identification of yeasts and/or fungal elements | Cerebrospinal fluid (CSF); Serum | Cryptococcus antigen |
| Microbiology - Serology of infection - Microbial antibody and/or antigen detection and/or quantitation | Blood; Plasma; Serum | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) IgG antibody; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) IgM antibody |
| Plasma; Serum | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) IgG antibody; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) IgM antibody | |
| Serum | Syphilis Treponema pallidum total antibody | |
| Hepatitis A virus antibody (anti-HAV) - IgM; Hepatitis A virus antibody (anti-HAV) - Total; Hepatitis B virus core antibody (anti-HBc) - IgM; Hepatitis B virus core antibody (anti-HBc) - Total; Hepatitis B virus envelope antibody (anti-HBe); Hepatitis B virus envelope antigen (HBe Ag); Hepatitis B virus surface antibody (anti-HBs); Hepatitis C virus antibody (anti-HCV) - Total; Human immunodeficiency virus type 1/2 (HIV-1/2) 1/2 antibodies; Rubella IgG antibody; Rubella IgM antibody; Syphilis Treponema pallidum antibody; Toxoplasma spp. IgG antibody; Toxoplasma spp. IgM antibody | ||
| Cytomegalovirus antibody (anti-CMV) IgM | ||
| Bordetella pertussis IgA; Bordetella pertussis IgG; Borrelia burgdorferi; Chlamydia trachomatis; Chlamydial spp. IgG antibody; Chlamydial group IgA antibody; Herpes simplex virus type 2 antibody (anti-HSV2) - IgG; Herpes simplex type 1 antibody (anti-HSV1) - IgG; Measles IgG antibody; Measles IgM antibody; Mumps virus IgG antibody; Mumps virus IgM antibody; Mycoplasma pneumoniae IgG antibody; Mycoplasma IgM antibody; Mycoplasma total antibody; Parvovirus IgG antibody; Parvovirus IgM antibody; Varicella zoster virus (VZV) IgG antibody; Varicella zoster virus IgM antibody | ||
| Barmah forest virus IgG antibody; Barmah forest virus IgM antibody; Coxiella burnetii (Q-fever) IgG phase 1 antibody; Coxiella burnetii (Q-fever) IgM phase 1 antibody; Ross River virus IgG antibody; Ross River virus IgM antibody | ||
| Cytomegalovirus antibody (anti-CMV) IgG; Cytomegalovirus antibody (anti-CMV) IgM; Epstein-Barr virus IgM antibody; Epstein-Barr virus nuclear antigen IgG antibody; Hepatitis B virus surface antigen (HBs Ag) - Confirmatory; Hepatitis C virus antibody (anti-HCV); Human T-lymphotropic virus type I/II (HTLV-I/II) antibody; Syphilis Treponema pallidum antibody | ||
| Coxiella burnetii (Q-fever) IgG phase 2 antibody; Coxiella burnetii (Q-fever) IgM phase 2 antibody |
Microbiology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
07 Jan 2025
Last Activity Date
30 Sep 2021
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Detection of faecal occult blood | Faeces | Blood |
| Chemical pathology - Investigation of malabsorption | Faeces | Faecal fat; Reducing substances |
| Immunopathology - Quantitative and/or qualitative investigation of proteins | Faeces | Calprotectin; Elastase |
| Microbiology - Bacteriology - Detection and identification of crystalline material | Synovial fluid | Crystal detection and identification |
| Microbiology - Bacteriology - Detection of pathogenic bacteria | Biopsy specimens; Blood; Cerebrospinal fluid (CSF); Faeces; Fluids; General swabs; Genital swabs; Pus; Respiratory specimens; Urine; Wound swabs | Pathogenic identification and antibiotic susceptibility |
| Pathogenic identification and antibiotic susceptibility | ||
| Blood | Pathogenic microorganisms | |
| Faeces; Fluids; Synovial fluid | Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | |
| Isolates | Carbapenem resistant Enterobacteriaceae (CRE) | |
| Rectal swabs | Carbapenem resistant Enterobacteriaceae (CRE) | |
| Rectal swabs; Vaginal swabs | Streptococcus group B screening | |
| Urine | Glucose; Proteins | |
| Casts; Crystals; Epithelial cells; Erythrocytes (red blood cells, RBC); Leucocytes (white blood cells, WBC) | ||
| Casts; Crystals; Epithelial cells; Erythrocytes (red blood cells, RBC); Glucose; Leucocytes (white blood cells, WBC); Proteins | ||
| Microbiology - Environmental investigations and/or infection control | Gastrointestinal endoscopes; Spore strips | Bacterial growth - Sterility |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (bacteria) | Aspirates; Bronchial washings; Bronchoalveolar lavage; Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs | Bordetella parapertussis; Bordetella pertussis |
| Faeces | Aeromonas spp.; Campylobacter spp.; Salmonella spp.; Shigella spp.; Yersinia enterocolitica | |
| Clostridioides difficile | ||
| Genital swabs; Liquid based cytology specimens; Rectal swabs; Throat swabs; Urine | Chlamydia trachomatis; Mycoplasma genitalium; Neisseria gonorrhoeae | |
| Genital swabs; Urethral swabs | Chlamydia trachomatis; Neisseria gonorrhoeae | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (protozoan parasites) | Faeces | Blastocystis hominis; Cryptosporidium spp.; Dientamoeba spp.; Entamoeba histolytica; Giardia spp. |
| Genital swabs; Liquid based cytology specimens; Urine | Trichomonas vaginalis | |
| Microbiology - Molecular biology - Detection, characterisation and/or quantitation of microbial nucleic acids (viruses) | Aspirates; Bronchial washings; Nasal swabs; Nasopharyngeal aspirate; Nasopharyngeal swabs; Throat swabs | Adenovirus; Human metapneumovirus; Influenza A virus; Influenza B virus; Parainfluenza virus type 1/2/3/4; Respiratory syncytial virus (RSV) A/B; Rhinovirus |
| Combined nose and throat swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Faeces | Norovirus | |
| General swabs | Herpes simplex virus (HSV); Varicella zoster virus (VZV) | |
| Liquid based cytology specimens | Human papilloma virus (HPV) | |
| Nasal swabs; Nasopharyngeal swabs; Oropharyngeal swabs | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) | ||
| Plasma | Human immunodeficiency virus type 1 (HIV-1) RNA; Human immunodeficiency virus type 2 (HIV-2) DNA | |
| Plasma; Serum | Hepatitis B virus (HBV) DNA; Hepatitis C virus (HCV) viral RNA | |
| Microbiology - Molecular biology - Surveillance programme for the detection of microbial nucleic acids (viruses) in accordance with Commonwealth and/or State Health protocols | Saliva | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID) |
| Microbiology - Mycobacteriology - Detection and identification of mycobacteria | Other body fluids; Sputum; Tissues; Urine | Mycobacteria detection |
| Sputum; Tissues; Urine | Mycobacteria detection | |
| Microbiology - Mycobacteriology - Tests for cell mediated immunity | Blood | Latent tuberculosis |
| Microbiology - Mycology - Detection of dermatophytes and other fungi causing cutaneous disease | Hair; Nails; Skin; Skin scrapings | Dermatophyte identification |
| Microbiology - Mycology - Detection, isolation and/or identification of yeasts and/or fungal elements | Hair; Nails; Skin; Skin scrapings | Fungi identification; Yeasts identification |
| Fungi identification; Yeasts identification | ||
| Microbiology - Parasitology - Detection of ova, cysts and parasites | Faeces | Cysts; Ova; Parasites |
| Microbiology - Virology - Detection of pathogenic viruses | Faeces | Adenovirus; Rotavirus |
Special Chemistry and Heavy Metals
ISO 15189 (2022)
Human Pathology
Medicare expiry date
07 Jan 2025
Last Activity Date
30 Sep 2021
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Biogenic amines | Plasma | Metanephrine; Normetanephrine |
| Urine | 5-Hydroxyindoleacetic acid (5-HIAA); Adrenaline; Dopamine; Metanephrine; Noradrenaline; Normetanephrine | |
| Chemical pathology - Detection and/or quantitation of tumour markers | Serum | Chromogranin A - Gen I |
| Chemical pathology - Determination of hormones and hormone binding proteins (other than thyroid function tests) | Serum | 17α-Hydroxyprogesterone |
| Chemical pathology - Investigation of malabsorption - Quantitation of solid tissue enzymes | Intestinal tissue | Lactase; Maltase; Sucrase |
| Chemical pathology - Investigation of maternal markers for pre-eclampsia | Serum | FMS-like tyrosine kinase 1 - Soluble; Placental growth factor (PGF, PLGF) |
| Chemical pathology - Investigation of maternal markers to detect foetal abnormality | Serum | Free β-human chorionic gonadotropin (free β-hCG); Placental growth factor (PGF, PLGF); Pregnancy associated plasma protein A (PAPP-A); α-Fetoprotein (AFP) |
| Chemical pathology - Trace element analysis | Blood | Arsenic; Cadmium; Lead; Mercury |
| Plasma; Serum | Aluminium; Chromium; Cobalt; Copper; Selenium; Zinc | |
| Urine | Antimony; Arsenic; Cadmium; Chromium; Cobalt; Copper; Iodine; Lead; Manganese; Mercury; Nickel; Selenium; Thallium; Vanadium; Zinc |
Toxicology
ISO 15189 (2022)
Human Pathology
Medicare expiry date
07 Jan 2025
Last Activity Date
30 Sep 2021
| Service | Product | Determinant |
|---|---|---|
| Chemical pathology - Analysis of drugs for toxicological (non-legal) purposes and ingested or absorbed toxic chemicals | Plasma; Serum; Urine | Ethanol |
| Urine | Barbiturates; Methadone metabolites | |
| 3,4-Methylenedioxymethamphetamine (MDMA); Amphetamines; Benzoylecgonine (ecgonine benzoate); Diazepam; Ecgonine methyl ester; Ephedrine; Methadone; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Morphine; Nordiazepam; Oxazepam; Phentermine; Pseudoephedrine (PSE); Synthetic cannabis; Temazepam; α-Hydroxyalprazolam | ||
| 2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP); Barbiturates; Buprenorphine; Cotinine; Fentanyl; Methadone metabolites; Oxycodone; Synthetic cannabis; Tramadol; Tricyclics |
ISO 15189 (2022)
Legal
Medicare expiry date
07 Jan 2025
Last Activity Date
30 Sep 2021
| Service | Product | Determinant |
|---|---|---|
| Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Opiates |
| Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure - Mobile testing service | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates |
| Medico legal drug testing AS/NZS 4308:2008, appendix A On-site screening procedure - Testing performed at client sites | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates |
| Medico legal drug testing AS/NZS 4308:2008, section 2 Specimen collection, storage, handling and dispatch | Urine | Colour; Creatinine; Temperature |
| Medico legal drug testing AS/NZS 4308:2008, section 3 General laboratory requirements | Urine | General laboratory requirements as described in AS/NZS 4308 |
| Medico legal drug testing AS/NZS 4308:2008, section 4 Laboratory screening procedures | Urine | Amphetamine type substances; Benzodiazepines; Cannabis metabolites; Cocaine metabolites; Creatinine; Opiates; Specific gravity; Urea; pH |
| Medico legal drug testing AS/NZS 4308:2008, section 5 Laboratory confirmatory procedures | Urine | (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone metabolite; (4-Methyl-1-naphthyl)(1-pentyl-1H-indol-3-yl)methanone; 1-(2-[4-Morpholinyl]ethyl)-1H-indol-3-yl-1-naphthalenylmethanone; 1-(5-Fluoropentyl)-1H-indol-3-yl-(2,2,3,3-tetramethylcyclopropyl)methanone metabolite; 1-(5-Hydroxypentyl)-1H-indol-3-yl-(4-methylnaphthalen-1-yl)methanone; 1-(5-Hydroxypentyl)-1H-indol-3-yl-(naphthalene-1-yl)methanone; 1-(Butyl-1H-indol-3-yl)-1-naphthalenylmethanone; 1-(Pentyl-1H-indol-3-yl)-1-naphthalenylmethanone; 11-nor-Δ9-Tetrahydrocannabinol-9-carboxylic acid glucuronide; 11-nor-δ-9-Tetrahydrocannabinol-9-carboxylic acid; 2-([1r,3s]-3-Hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol; 3,4-Methylenedioxy-N-ethylamphetamine (MDEA); 3,4-Methylenedioxyamphetamine (MDA); 3,4-Methylenedioxymethamphetamine (MDMA); 3,4-Methylenedioxypyrovalerone (MDPV); 4-(3-(1-Naphthoyl)-1H-indol-1-yl-butanoic acid; 4-Hydroxy(1-(2-[4-morpholinyl])ethyl)-1H-indol-3-yl-1-naphthalenyl-methanone; 5-(3-1-Naphthoyl)-1H-indol-1-yl-pentanoic acid; 6-Acetylmorphine; 7-Amino-clonazepam; 7-Amino-flunitrazepam; 7-Amino-nitrazepam; Amphetamines; Benzoylecgonine (ecgonine benzoate); Butyolone; Cannabicyclohexanol; Codeine; Codeine-6-glucuronide (codeine-6-β-D-glucuronide); Diazepam; Ecgonine methyl ester; Ephedrine; Ethylone; Mephedrone; Methedrone; Methylamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Morphine; Morphine-3-glucuronide (morphine-3-β-D-glucuronide); Morphine-6-glucuronide (morphine-6-β-D-glucuronide); Nordiazepam; Oxazepam; Phentermine; Pseudoephedrine (PSE); Pyrovalerone; Temazepam; Zolpidem; α-Hydroxyalprazolam |
| Medico legal drug testing AS/NZS 4760, appendix B Additional testing | Oral fluid | Phentermine; Pholcodine |
| Medico legal drug testing AS/NZS 4760, section 2 Collection, storage, handling and dispatch | Oral fluid | Handling and dispatch; Sample collection and storage |
| Medico legal drug testing AS/NZS 4760, section 4 Laboratory screen testing | Oral fluid | Amphetamine type substances; Cocaine; Cocaine metabolites; Δ-9-Tetrahydrocannabinol (THC-Δ9) |
| Medico legal drug testing AS/NZS 4760, section 5 Laboratory confirmatory procedures | Oral fluid | 3,4-Methylenedioxyamphetamine (MDA); 3,4-Methylenedioxymethamphetamine (MDMA); 6-Acetylmorphine; Amphetamines; Benzoylecgonine (ecgonine benzoate); Cocaine; Codeine; Ecgonine methyl ester; Methylamphetamine; Methylenedioxyamphetamine; Methylenedioxymethylamphetamine; Morphine; Oxycodone; Δ-9-Tetrahydrocannabinol (THC-Δ9) |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
2203
Site No.
2196
Print date
19 Apr 2024
END OF SCOPE
